Generali Investments CEE investicni spolecnost a.s. Buys 11,695 Shares of Biogen Inc. $BIIB

Key Points

• Generali Investments CEE increased its stake in Biogen Inc. by 43.2%, acquiring an additional 11,695 shares, bringing its total holdings to 38,755 shares valued at approximately $4.87 million.
• Insider Priya Singhal sold 517 shares of Biogen, indicating an 8.22% decrease in her position, while Rachid Izzar sold 2,223 shares, marking a 25.99% decrease in his holdings.
• Biogen reported a Q2 earnings per share (EPS) of $5.47, exceeding the analysts' expectations, and raised its FY 2025 EPS guidance to between 15.500 and 16.000.

Generali Investments CEE investicni spolecnost a.s. raised its stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 43.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,755 shares of the biotechnology company's stock after acquiring an additional 11,695 shares during the period. Generali Investments CEE investicni spolecnost a.s.'s holdings in Biogen were worth $4,867,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Biogen by 6.5% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 416,960 shares of the biotechnology company's stock worth $57,057,000 after purchasing an additional 25,464 shares during the period. Asset Management One Co. Ltd. raised its stake in shares of Biogen by 5.5% during the 1st quarter. Asset Management One Co. Ltd. now owns 61,420 shares of the biotechnology company's stock worth $8,405,000 after purchasing an additional 3,194 shares during the period. Point72 Europe London LLP bought a new stake in shares of Biogen during the 1st quarter worth $11,286,000. Motley Fool Asset Management LLC raised its stake in shares of Biogen by 64.7% during the 1st quarter. Motley Fool Asset Management LLC now owns 6,809 shares of the biotechnology company's stock worth $932,000 after purchasing an additional 2,676 shares during the period. Finally, Assenagon Asset Management S.A. raised its stake in shares of Biogen by 3.1% during the 1st quarter. Assenagon Asset Management S.A. now owns 44,796 shares of the biotechnology company's stock worth $6,130,000 after purchasing an additional 1,336 shares during the period. 87.93% of the stock is currently owned by institutional investors.

Insider Transactions at Biogen

In other Biogen news, insider Priya Singhal sold 517 shares of Biogen stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $133.55, for a total transaction of $69,045.35. Following the completion of the transaction, the insider owned 5,772 shares of the company's stock, valued at $770,850.60. The trade was a 8.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Rachid Izzar sold 2,223 shares of Biogen stock in a transaction dated Tuesday, July 8th. The shares were sold at an average price of $135.00, for a total value of $300,105.00. Following the transaction, the insider directly owned 6,330 shares of the company's stock, valued at $854,550. The trade was a 25.99% decrease in their position. The disclosure for this sale can be found here. 0.18% of the stock is owned by insiders.

Biogen Stock Up 1.1%

BIIB stock opened at $140.08 on Wednesday. The company has a quick ratio of 1.79, a current ratio of 2.50 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $20.54 billion, a PE ratio of 13.39, a PEG ratio of 1.09 and a beta of 0.11. Biogen Inc. has a twelve month low of $110.04 and a twelve month high of $195.00. The stock has a 50-day simple moving average of $136.53 and a two-hundred day simple moving average of $130.53.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its earnings results on Thursday, July 31st. The biotechnology company reported $5.47 earnings per share for the quarter, beating analysts' consensus estimates of $3.93 by $1.54. The business had revenue of $2.65 billion during the quarter, compared to analyst estimates of $2.32 billion. Biogen had a return on equity of 13.85% and a net margin of 15.31%.The company's quarterly revenue was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $5.28 EPS. Biogen has set its FY 2025 guidance at 15.500-16.000 EPS. On average, equities analysts predict that Biogen Inc. will post 15.83 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Royal Bank Of Canada lifted their target price on Biogen from $208.00 to $219.00 and gave the stock an "outperform" rating in a research note on Friday, August 1st. Wedbush restated a "neutral" rating and issued a $121.00 price objective on shares of Biogen in a research note on Thursday, June 12th. Truist Financial assumed coverage on Biogen in a research note on Monday, July 21st. They issued a "hold" rating and a $142.00 price objective on the stock. HC Wainwright boosted their price objective on Biogen from $187.00 to $194.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Finally, Wall Street Zen upgraded Biogen from a "buy" rating to a "strong-buy" rating in a research note on Sunday. Eleven equities research analysts have rated the stock with a Buy rating and twenty have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $182.04.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.